1-2 of 2
Gautham Borthakur
Close
Sort by
Journal Articles

Genomic context and TP53 allele frequency define clinical outcomes in TP53 -mutated myelodysplastic syndromes

Clinical Trials & Observations
Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Christopher B. Benton, Caleb A. Class, Kelly S. Chien, Koji Sasaki, Kiran Naqvi, Yesid Alvarado, Tapan M. Kadia, Farhad Ravandi, Naval Daver, Koichi Takahashi, Elias Jabbour, Gautham Borthakur, Naveen Pemmaraju, Marina Konopleva, Kelly A. Soltysiak, Sherry R. Pierce, Carlos E. Bueso-Ramos, Keyur P. Patel, Hagop Kantarjian, Guillermo Garcia-Manero
Journal: Blood Advances
Blood Adv (2020) 4 (3): 482–495.
https://doi.org/10.1182/bloodadvances.2019001101
Published: 2020
Includes: Supplemental data
Journal Articles

NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy

Clinical Trials & Observations
Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Koji Sasaki, Keyur Patel, Irene Ganan-Gomez, Elias Jabbour, Tapan Kadia, Farhad Ravandi, Courtney DiNardo, Gautham Borthakur, Koichi Takahashi, Marina Konopleva, Rami S. Komrokji, Amy DeZern, Teodora Kuzmanovic, Jaroslaw Maciejewski, Sherry Pierce, Simona Colla, Mikkael A. Sekeres, Hagop Kantarjian, Carlos Bueso-Ramos, Guillermo Garcia-Manero
Journal: Blood Advances
Blood Adv (2019) 3 (6): 922–933.
https://doi.org/10.1182/bloodadvances.2018026989
Published: 2019
Includes: Supplemental data